Cancer Immunology and Immunotherapy
A section of Cancers (ISSN 2072-6694).
Section Information
Cancer remains a leading cause of death in Western countries, and treatment of advanced stages of the disease is still limited. Discoveries in the field of cancer immunology and progress in immunotherapy as the first line therapy bring the most exciting times for delivering a potential cure for advanced cancer. Understanding the common mechanisms of tumorigenesis, including changes in tumor microenvironment, immune evasion, and antitumor immune responses, is pivotal for further development of novel therapeutics.
Following early discoveries of connection of autoimmune diseases with cancer, recent advances in T cell biology have revolutionized cancer therapy. Most importantly, standard-of-care chemotherapy and radiation effects have also been linked to immune cell-mediated anticancer effects.
Importantly, multiple clinical trials using checkpoint blockade agents, ATC transfer therapies, and cancer vaccines show much better outcomes than the most effective chemotherapeutic agents.
The aim of this Special Section is to publish findings that relate to cancer immunology and therapies based on the immune-targeting. Topics include, but are not limited to:
- checkpoint blockade
- innate immunity
- adaptive responses
- vaccines
- ATC transfer therapy
- immune evasion
- immune switch
- immunosuppression
- tumor microenvironment
Editorial Board
Topical Advisory Panel
Special Issues
Following special issues within this section are currently open for submissions:
- Immune Checkpoint Inhibitors in Cancer Therapy—How Can We Improve Clinical Benefits? (Deadline: 30 June 2022)
- Advances in Understanding the Immune Network of Thyroid Cancers (Deadline: 30 June 2022)
- Natural Killer Cells in Cancer Biology and Therapy (Deadline: 30 June 2022)
- Tumor Vasculature and Immunity in Cancer (Deadline: 30 June 2022)
- Non-Hodgkin Lymphomas (Deadline: 10 July 2022)
- Immunotherapy for Solid Tumors (Deadline: 15 July 2022)
- Cancer Immunotherapy and Immune-Related Adverse Events (Deadline: 15 July 2022)
- Advances in Immuno-Oncology Research (Deadline: 20 July 2022)
- The Biology of Hepatocellular Carcinoma: Implications for Genomic and Immune Therapies (Deadline: 31 July 2022)
- Advances in Cancer Vaccines (Deadline: 31 July 2022)
- Unnatural Killers for Immunotherapy: Harnessing NK Cells and Their Diversity in the Tumor Microenvironment (Deadline: 31 July 2022)
- Oncolytic Viruses as Cancer Immunotherapy Agents (Deadline: 10 August 2022)
- Effects of TGF-Beta on Cancer Cell Metabolism (Deadline: 15 August 2022)
- Neoplastic Complications of Immune-Mediated Gastrointestinal Disorders (Deadline: 15 August 2022)
- The Role of Immunotherapy in Squamous Cell Carcinoma (Deadline: 15 August 2022)
- Perspectives of Immunotherapy in Tumors of the Gastrointestinal Tract (Deadline: 20 August 2022)
- Engineering the Tumor Immune Microenvironment (Deadline: 31 August 2022)
- New Approaches to Personalise Therapy for Colorectal Cancer (Deadline: 31 August 2022)
- Novel Therapeutic Strategies for Lung Cancer in the Era of Personalized Treatment (Deadline: 10 September 2022)
Beyond Checkpoints––the HLA System and other New Targets
(Deadline: 10 September 2022)- Microbial-Based Cancer Therapies (Deadline: 15 September 2022)
- Immunotherapy in Melanoma: Recent Advances and Future Directions (Deadline: 15 September 2022)
- Mechanisms of Cancer Immunotherapy and Immune-Escape (Deadline: 15 September 2022)
- Targeted Immunotherapies for Cancers (Deadline: 15 September 2022)
- Immune Responses in Brain Cancer (Deadline: 15 September 2022)
- Cancer-Associated Fibroblasts and Treatment Response (Deadline: 15 September 2022)
- Advances in Cancer Immunotherapy (Deadline: 15 September 2022)
- Advances in Immunotherapy for Hematological Malignancies (Deadline: 20 September 2022)
- Immune-Humanized Patient-Derived Xenograft Mouse Models for Cancer Research (Deadline: 30 September 2022)
- Recent Advances in Mechanisms of Resistance and Targeted Therapy in Melanoma (Deadline: 30 September 2022)
- Tumor Microenvironment and Molecular Aberrations Convey Immune Evasion (Deadline: 15 October 2022)
- Advanced Neuroendocrine Tumors (Deadline: 20 October 2022)
- Cancer and Humoral Immunity (Deadline: 20 October 2022)
- The Roles of Innate Lymphoid Cells in Cancer (Deadline: 31 October 2022)
- Tumor-Immune Microenvironment in Renal Cell Carcinoma (Deadline: 31 October 2022)
- Cell Therapy, Bispecific Antibodies and other Immunotherapies Against Cancer (Deadline: 15 November 2022)
- Microbiome-Based Interventions in Cancer Immunotherapy (Deadline: 15 November 2022)
- Immunotherapy of Triple-Negative Breast Cancer (Deadline: 15 November 2022)
- Mechanisms of Resistance to Cancer Immunotherapy (Deadline: 15 November 2022)
- Cancer Immunotherapy: Focus on Multidisciplinary Approaches and Predictive Biomarkers (Deadline: 15 November 2022)
- Natural Killer Cells—Innate Cancer Defense Cells under the Influence of Metabolism and Aging (Deadline: 30 November 2022)
- Immunotherapy in Thoracic Oncology: Incredible Progress and Remaining Challenges (Deadline: 1 December 2022)
- Antigens in Cancer (Deadline: 13 December 2022)
- Research in Personalized Cancer Vaccine (Deadline: 15 December 2022)
- PET/CT in Tumor Immunotherapy Assessment (Deadline: 15 December 2022)
- Tumor Immunology and Immunotherapy Resistance—Feature Paper in Section "Cancer Immunology and Immunotherapy" in 2022 (Deadline: 15 December 2022)
- Cytokines in Clinical Cancer Immunotherapy (Deadline: 15 December 2022)
- Targeted Treatment for Immunochemotherapy in Cancer (Deadline: 30 December 2022)
- Targeted Treatment and Immunotherapy for Hepato-Biliary Tumors (Deadline: 31 December 2022)
- T Cell and Immune Checkpoint in Cancer (Deadline: 15 January 2023)
- The Impact of CD4 in Cancer Immunotherapy (Deadline: 15 January 2023)
- Immunity and Gastrointestinal Cancer (Deadline: 15 February 2023)
- Dendritic Cells in Cancer Immunology and Immunotherapy (Deadline: 15 February 2023)
- Immunotherapy in Recurrent Glioblastoma (Deadline: 28 February 2023)
- Current Advances in Targeting Tumor-Associated Antigens (Deadline: 15 March 2023)
- Mechanisms of Immunosuppression in Cancer (Deadline: 10 April 2023)
Topical Collections
Following topical collections within this section are currently open for submissions:
